Janus Henderson Group PLC Buys New Holdings in Amicus Therapeutics, Inc. (FOLD)

Janus Henderson Group PLC bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 7,027,010 shares of the biopharmaceutical company’s stock, valued at approximately $70,762,000. Janus Henderson Group PLC owned about 4.27% of Amicus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. BNP Paribas Arbitrage SA raised its holdings in shares of Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after buying an additional 66,209 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Amicus Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock valued at $5,541,000 after buying an additional 41,711 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Amicus Therapeutics in the second quarter valued at about $1,057,000. Geode Capital Management LLC raised its holdings in shares of Amicus Therapeutics by 4.7% in the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock valued at $8,323,000 after buying an additional 52,003 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares during the last quarter.

Shares of Amicus Therapeutics, Inc. (FOLD) opened at 14.24 on Thursday. The firm’s market capitalization is $2.34 billion. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60. The stock has a 50 day moving average of $14.26 and a 200 day moving average of $10.77.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. During the same period in the previous year, the firm earned ($0.40) EPS. On average, analysts predict that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Janus Henderson Group PLC Buys New Holdings in Amicus Therapeutics, Inc. (FOLD)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://ledgergazette.com/2017/10/12/janus-henderson-group-plc-buys-new-holdings-in-amicus-therapeutics-inc-fold.html.

FOLD has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital boosted their price target on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $18.00 price target (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Two research analysts have rated the stock with a hold rating and eight

Other large investors have also made changes to their positions in the company. BNP Paribas Arbitrage SA raised its holdings in shares of Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after buying an additional 66,209 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Amicus Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock valued at $5,541,000 after buying an additional 41,711 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Amicus Therapeutics in the second quarter valued at about $1,057,000. Geode Capital Management LLC raised its holdings in shares of Amicus Therapeutics by 4.7% in the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock valued at $8,323,000 after buying an additional 52,003 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares during the last quarter.

Shares of Amicus Therapeutics, Inc. (FOLD) opened at 14.24 on Thursday. The firm’s market capitalization is $2.34 billion. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60. The stock has a 50 day moving average of $14.26 and a 200 day moving average of $10.77.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. During the same period in the previous year, the firm earned ($0.40) EPS. On average, analysts predict that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Janus Henderson Group PLC Buys New Holdings in Amicus Therapeutics, Inc. (FOLD)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://ledgergazette.com/2017/10/12/janus-henderson-group-plc-buys-new-holdings-in-amicus-therapeutics-inc-fold.html.

FOLD has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital boosted their price target on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $18.00 price target (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Amicus Therapeutics has an average rating of “Buy” and a consensus target price of $17.81.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply